Laura M. Sanz

TL;DR: Chemical structures and associated data suggest several novel mechanisms of antimalarial action, such as inhibition of protein kinases and host–pathogen interaction related targets.

TL;DR: DDD107498 was developed from a screening programme against blood-stage malaria parasites and its molecular target has been identified as translation elongation factor 2 (eEF2), which is responsible for the GTP-dependent translocation of the ribosome along messenger RNA, and is essential for protein synthesis.

TL;DR: ELQ-300, a 4(1H)-quinolone-3-diarylether, which targets the liver and blood stages, including the forms that are crucial to disease transmission (gametocytes, zygotes, and ookinetes), has potential as a new drug for the treatment, prevention, and, ultimately, eradication of human malaria.

TL;DR: The results demonstrate that targeting ATP4 has great potential to deliver useful drugs for malaria eradication and suggest that inhibitors of PfATP4 have highly attractive features for fast-acting antimalarials to be used in the global eradication campaign.

TL;DR: The ability of MMV390048 to block all life cycle stages of the malaria parasite suggests that this compound should be further developed and may contribute to malaria control and eradication as part of a single-dose combination treatment.